300 related articles for article (PubMed ID: 30540857)
1. Neutralization of Clostridium difficile toxin B with VHH-Fc fusions targeting the delivery and CROPs domains.
Hussack G; Ryan S; van Faassen H; Rossotti M; MacKenzie CR; Tanha J
PLoS One; 2018; 13(12):e0208978. PubMed ID: 30540857
[TBL] [Abstract][Full Text] [Related]
2. Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.
Andersen KK; Strokappe NM; Hultberg A; Truusalu K; Smidt I; Mikelsaar RH; Mikelsaar M; Verrips T; Hammarström L; Marcotte H
Infect Immun; 2016 Feb; 84(2):395-406. PubMed ID: 26573738
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography.
Orth P; Xiao L; Hernandez LD; Reichert P; Sheth PR; Beaumont M; Yang X; Murgolo N; Ermakov G; DiNunzio E; Racine F; Karczewski J; Secore S; Ingram RN; Mayhood T; Strickland C; Therien AG
J Biol Chem; 2014 Jun; 289(26):18008-21. PubMed ID: 24821719
[TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of Clostridium difficile toxin-specific single-domain antibodies.
Hussack G; Arbabi-Ghahroudi M; Mackenzie CR; Tanha J
Methods Mol Biol; 2012; 911():211-39. PubMed ID: 22886255
[TBL] [Abstract][Full Text] [Related]
5. In vivo neutralization of α-cobratoxin with high-affinity llama single-domain antibodies (VHHs) and a VHH-Fc antibody.
Richard G; Meyers AJ; McLean MD; Arbabi-Ghahroudi M; MacKenzie R; Hall JC
PLoS One; 2013; 8(7):e69495. PubMed ID: 23894495
[TBL] [Abstract][Full Text] [Related]
6. Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2.
Dong J; Huang B; Wang B; Titong A; Gallolu Kankanamalage S; Jia Z; Wright M; Parthasarathy P; Liu Y
Sci Rep; 2020 Oct; 10(1):17806. PubMed ID: 33082473
[TBL] [Abstract][Full Text] [Related]
7. A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection.
Vrentas CE; Moayeri M; Keefer AB; Greaney AJ; Tremblay J; O'Mard D; Leppla SH; Shoemaker CB
J Biol Chem; 2016 Oct; 291(41):21596-21606. PubMed ID: 27539858
[TBL] [Abstract][Full Text] [Related]
8. Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab.
Hernandez LD; Kroh HK; Hsieh E; Yang X; Beaumont M; Sheth PR; DiNunzio E; Rutherford SA; Ohi MD; Ermakov G; Xiao L; Secore S; Karczewski J; Racine F; Mayhood T; Fischer P; Sher X; Gupta P; Lacy DB; Therien AG
J Mol Biol; 2017 Apr; 429(7):1030-1044. PubMed ID: 28232034
[TBL] [Abstract][Full Text] [Related]
9. Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice.
Godakova SA; Noskov AN; Vinogradova ID; Ugriumova GA; Solovyev AI; Esmagambetov IB; Tukhvatulin AI; Logunov DY; Naroditsky BS; Shcheblyakov DV; Gintsburg AL
Toxins (Basel); 2019 Aug; 11(8):. PubMed ID: 31394847
[TBL] [Abstract][Full Text] [Related]
10. High-Resolution Epitope Positioning of a Large Collection of Neutralizing and Nonneutralizing Single-Domain Antibodies on the Enzymatic and Binding Subunits of Ricin Toxin.
Vance DJ; Tremblay JM; Rong Y; Angalakurthi SK; Volkin DB; Middaugh CR; Weis DD; Shoemaker CB; Mantis NJ
Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021300
[TBL] [Abstract][Full Text] [Related]
11. Targeting surface-layer proteins with single-domain antibodies: a potential therapeutic approach against Clostridium difficile-associated disease.
Kandalaft H; Hussack G; Aubry A; van Faassen H; Guan Y; Arbabi-Ghahroudi M; MacKenzie R; Logan SM; Tanha J
Appl Microbiol Biotechnol; 2015 Oct; 99(20):8549-62. PubMed ID: 25936376
[TBL] [Abstract][Full Text] [Related]
12. Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection.
Yang Z; Shi L; Yu H; Zhang Y; Chen K; Saint Fleur A; Bai G; Feng H
Pathog Dis; 2016 Oct; 74(7):. PubMed ID: 27502696
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain.
Hussack G; Arbabi-Ghahroudi M; van Faassen H; Songer JG; Ng KK; MacKenzie R; Tanha J
J Biol Chem; 2011 Mar; 286(11):8961-76. PubMed ID: 21216961
[TBL] [Abstract][Full Text] [Related]
14. Stepwise engineering of heterodimeric single domain camelid VHH antibodies that passively protect mice from ricin toxin.
Vance DJ; Tremblay JM; Mantis NJ; Shoemaker CB
J Biol Chem; 2013 Dec; 288(51):36538-47. PubMed ID: 24202178
[TBL] [Abstract][Full Text] [Related]
15. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.
Yang Z; Schmidt D; Liu W; Li S; Shi L; Sheng J; Chen K; Yu H; Tremblay JM; Chen X; Piepenbrink KH; Sundberg EJ; Kelly CP; Bai G; Shoemaker CB; Feng H
J Infect Dis; 2014 Sep; 210(6):964-72. PubMed ID: 24683195
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of toxin- and virus-neutralizing capacity of single-domain antibody fragments by N-glycosylation.
Harmsen MM; van Solt CB; Fijten HP
Appl Microbiol Biotechnol; 2009 Oct; 84(6):1087-94. PubMed ID: 19455325
[TBL] [Abstract][Full Text] [Related]
17. Deciphering the domain specificity of C. difficile toxin neutralizing antibodies.
Cole LE; Li L; Jetley U; Zhang J; Pacheco K; Ma F; Zhang J; Mundle S; Yan Y; Barone L; Rogers C; Beltraminelli N; Quemeneur L; Kleanthous H; Anderson SF; Anosova NG
Vaccine; 2019 Jun; 37(29):3892-3901. PubMed ID: 31122858
[TBL] [Abstract][Full Text] [Related]
18. Biparatopic single-domain antibodies against Axl achieve ultra-high affinity through intramolecular engagement.
Henry KA; Nguyen TD; Baral TN; Hussack G; Raphael S; Arbabi-Ghahroudi M; Robert A; Durocher Y; Wu C; Jaramillo ML; MacKenzie CR
Biochem Biophys Res Commun; 2021 Jul; 562():154-161. PubMed ID: 34058562
[TBL] [Abstract][Full Text] [Related]
19. Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.
Villafuerte Gálvez JA; Kelly CP
Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):611-622. PubMed ID: 28636484
[TBL] [Abstract][Full Text] [Related]
20. Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling.
Hernandez LD; Racine F; Xiao L; DiNunzio E; Hairston N; Sheth PR; Murgolo NJ; Therien AG
Antimicrob Agents Chemother; 2015 Feb; 59(2):1052-60. PubMed ID: 25451052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
